Maria Loukopoulou,Anastasia Kottorou,Angelos Koutras et al. Maria Loukopoulou et al.

This truly highlights liquid biopsy as a valuable, minimally invasive tool. However, there are still some big challenges to treat.

Snježana Kaštelan,Fanka Gilevska,Zora Tomić et al. Snježana Kaštelan et al.

In parallel, liquid biopsy has emerged as a minimally invasive approach for real-time disease monitoring....This review synthesises current knowledge of molecular and liquid biopsy biomarkers in ocular melanoma, highlighting their relevance for diagnosis, prognosis, and treatment personalisation....The integration of established tissue-based molecular markers with novel liquid biopsy technologies will enable a unique framework for biomarker-guided precision oncology and risk-adapted surveillance in uveal and conjunctival melanoma, offering insight into strategies for early detection, therapeutic

Theodora Chindea,Alina-Teodora Nicu,Gheorghe Dănuț Cimponeriu et al. Theodora Chindea et al.

This review explores the "nutri-epigenetic" interface, positioning liquid biopsy as a critical technology for translating dietary impacts into actionable clinical biomarkers.

Keren Rouvinov,Rashad Naamneh,Alexander Yakobson et al. Keren Rouvinov et al.

Results: Emerging evidence shows that ctDNA-based liquid biopsy enables dynamic, real-time tracking of tumor evolution and therapeutic resistance....Conclusions: ctDNA analysis via liquid biopsy is poised to revolutionize cancer care by offering a non-invasive, precise, and adaptive tool for tumor characterization and monitoring....With continued progress, ctDNA-based liquid biopsy is likely to become a cornerstone of routine oncology practice.

Diana Maria Orzata,Adrian-Iosif Moldoveanu,Gabriel Veniamin Cozma et al. Diana Maria Orzata et al.

Despite these distinctive features, they remain relatively underrepresented in biomarker-driven clinical frameworks, and evidence specific to liquid biopsy performance in this subgroup is fragmented....Although liquid biopsy is now integral to precision oncology across multiple solid tumors, its role in mucinous disease remains incompletely defined....This review synthesizes evidence on liquid biopsy and molecular biomarkers in mucinous appendiceal and colorectal tumors, with emphasis on circulating tumor DNA (ctDNA) and emerging multi-analyte approaches....Rather than extrapolating from non-mucinous colorectal cancer paradigms, we examine liquid biopsy performance through the lens of mucinous tumor biology and peritoneal compartmentalization....We further outline practical considerations for integrating liquid biopsy results into multidisciplinary decision-making in mucinous malignancies.

Juan Zhang,Jie Shen Juan Zhang

This review focuses on circulating tumor cells (CTCs) as a liquid biopsy cornerstone, emphasizing their unique biological characteristics and clinical potential. CTCs, shed from primary or metastatic tumors into the bloodstream, enable minimally invasive and serial sampling....We synthesize the latest progress in Raman-based platforms for CTC analysis and discuss current challenges and future trajectories for integrating Raman imaging into standardized liquid biopsy workflows for oncology.

Vivek Subbiah,Elie Rassy,Frank A Greco Vivek Subbiah

We examine the clinical utility of comprehensive genomic profiling, gene expression profiling, and liquid biopsy technologies, while addressing implementation challenges and future directions.

Ruisa Nishida,Masashi Takahashi,Kaori Ide et al. Ruisa Nishida et al.

To date, no studies have determined that liquid biopsy using miRNA can specifically identify dogs with cancer from a mixed population of dogs with and without non-malignant diseases.

Weizhao Yao,Yaru Li,Yuling Du et al. Weizhao Yao et al.

By integrating these modalities, the PACC platform overcomes serum matrix interference and biomarker scarcity, providing a scalable and low-cost avenue for detecting low-abundance protein biomarkers and advancing liquid biopsy toward precision oncology.

Jianchun Duan,Qiang Gao,Zhijie Wang et al. Jianchun Duan et al.

Although circulating cell-free DNA (cfDNA) methylation has emerged as the mainstream approach in multi-cancer detection blood tests (MCDBTs), the potential of integrating proteins and mutations, to enhance its performance remains unclear. T...